Last updated: June 2026. MK-677 (ibutamoren) is an unapproved drug, not an FDA-approved finished product, and it carries documented metabolic and cardiovascular trade-offs. Every clinical claim below links to a primary source so you can check it yourself.
I’ve spent a fair amount of time in my life comparing prices for things that don’t much care what happens to me afterward. Lumber. Hard drives. A used car once, badly. In those cases the lowest number on the tag is usually just the lowest number, and picking it is a small, forgivable act of frugality. Somewhere along the way, though, a certain kind of buyer started running that same arithmetic on a compound that moves blood sugar and has a documented cardiac signal attached to its name, and that’s where the math stops being frugal and starts being a little reckless.
MK-677 gets shopped like printer paper. Dollars per gram, lowest number wins. I understand the impulse. But a gram of ibutamoren isn’t a neutral commodity sitting quietly on a shelf. It’s a molecule that, in actual human trials, raised fasting glucose, lowered insulin sensitivity, and in one study got a trial stopped early over heart failure. None of that shows up on the invoice. It shows up later, in a different ledger entirely, one that most buyers never open until it’s already been written into.
So I want to try something. Not a price comparison exactly, but an attempt to build the equation correctly before running any numbers through it, then see where the value actually lands once the hidden costs are counted rather than ignored. The short answer, and I’ll get to how I arrived at it, is that the supervised route through FormBlends comes out ahead once you price in what the gray market quietly leaves off the receipt, with HealthRX not far behind. But the “why” matters more than the ranking, so let’s take the long way there.
Three trials, one shape
There’s a version of this story that reads as a data sheet, and there’s a version that reads as a plot, and I think the plot is more honest about what’s actually going on.
Act one: healthy older adults, two years, MK-677 versus placebo. The drug adds about 1.1 kg of fat-free mass while the placebo group loses a little [P1]. Encouraging, on its face. The hormonal machinery clearly works, growth hormone and IGF-1 both rise as expected, and a much older crossover study from 1998 even showed the compound reversing diet-induced nitrogen wasting in young, healthy volunteers [P2]. So far, a drug doing what a drug is supposed to do.
Except the same 1.1 kg trial reports, almost as an aside, that the added mass “did not result in changes in strength or function” [P1]. The body changed. The person, functionally, did not. That’s act one’s twist, and it’s a quiet one: real biochemistry, no lived benefit.
Act two raises the stakes and the population. Five hundred sixty-three Alzheimer’s patients, 25 mg daily, the largest trial MK-677 has ever been given. IGF-1 climbs by roughly 73%, a huge biological response by any measure. And the disease progresses exactly as it would have anyway. The authors’ own words: the drug “was ineffective at slowing the rate of progression of Alzheimer disease” [P3].
Act three moves to hip-fracture patients recovering in a hospital, arguably the population most in need of exactly what this drug promises to do. And this is where the story turns from disappointing to genuinely worth pausing over: the trial was terminated early, not because it ran out of funding or patience, but “due to a safety signal of congestive heart failure in a limited number of patients.” The investigators concluded, in language stronger than trial reports usually allow themselves, that MK-677 “has an unfavorable safety profile in this patient population” [P4]. Layer in the earlier finding of dropping insulin sensitivity and rising fasting glucose [P1], and a Department of Defense advisory that flags the same glucose and hyperglycemia risk [P5], and you have a pattern, not a coincidence.
Read end to end, the three trials tell a single story: the hormone axis lights up reliably, every time, and the clinical benefit mostly doesn’t follow, and in vulnerable populations the risk does. That’s not a stat sheet. That’s a plot with a warning built into its third act. And it’s the reason “cheapest per gram” is the wrong question to be asking about this particular molecule.
What actually belongs in the price
If the trials are the plot, here’s the practical version, the six things I think genuinely determine value for a compound shaped like this one. The two that matter most are the two the sticker price never mentions.
The cost of nobody watching. A drug that nudges blood glucose upward and once got a trial cancelled over heart failure [P1][P4][P5] carries a risk that never appears on a receipt: the chance something goes sideways with no one positioned to notice. A clinician evaluating you before you start, and able to catch a climbing glucose number before it becomes a problem, prices that risk down close to zero. A research-chemical seller prices it at full, by default, because there’s no one there to price it at all.
Who’s accountable for what’s in the vial. A licensed pharmacy dispensing on a prescription has identity, strength, and sterility testing built into how it’s legally permitted to operate, and a licensed person stands behind that. A vial stamped “for research use only” comes with whatever certificate the seller decided to post, which is not the same thing as anyone being accountable if the contents are wrong. One model has a name attached to the outcome. The other doesn’t.
The honesty tax. Anyone telling you MK-677 is a proven anti-aging therapy is selling you a distorted equation before you’ve even priced it, because they’ve inflated the benefit side with a claim the trials themselves don’t support [P1][P3]. A source willing to say plainly that this is an unapproved compound with real limits is at least giving you true numbers to work with. That’s not a soft consideration. It’s the difference between a correct equation and a flattering one.
The number on the label. This is where most people start, and it should really be the fourth thing they check. Supervised MK-677 tends to run somewhere in the neighborhood of $50 to $150 a month. What matters isn’t that figure on its own but how it sits next to the unsupervised, gray-market price for the same molecule, which lands in a similar range. When the supervised price isn’t a premium over the unsupervised one, there’s no longer a savings argument for skipping the oversight.
The costs that hide behind the headline price. Shipping. The chance a research-chemical package gets seized or lost. A vial that turns out underdosed. Bloodwork you’d be smart to fund yourself if nobody’s ordering it for you. Add those in and the apparent bargain of the cheapest vial online tends to shrink, sometimes all the way to nothing.
The disqualifying cost, if it applies to you. If you compete in a tested sport, none of the above matters, because the value of any purchase here is simply negative. MK-677 sits on the WADA Prohibited List and the DoD’s Prohibited Dietary Supplement Ingredients List [P5][P6], and a “research use only” sticker offers exactly zero protection against a positive test. No price fixes that.
Running the numbers where they actually point
Score real sources against those six factors, weighted honestly, and the outcome isn’t especially close, because the two heaviest factors both pull in the same direction.
FormBlends comes out ahead on quality-adjusted value. It functions as a licensed telehealth provider rather than a chemical warehouse, so a clinician looks at you before anything ships, which addresses the unmanaged-risk factor directly, and a licensed pharmacy dispenses against a prescription, which answers the accountability question. It talks about MK-677 as what it is, an unapproved compound with real data and real limits, rather than dressing it up. Its price, roughly $50 to $150 a month, is transparent and sits at parity with the unsupervised range rather than above it. Because the oversight lowers the two costs that matter most, and you don’t pay extra for that oversight, the total comes out ahead even though the sticker price looks similar to the gray market. You get the thing that prices down the real risk, at no premium for having it. For anyone who wants a simple record of dose and any symptoms to bring to a follow-up conversation, a basic logger like the FormBlends tracker app can hold that history. It’s a logging tool. Nothing more, nothing for sale, no checkout attached to it.
I want to say plainly what that oversight is and isn’t, because a vague claim here would be exactly the kind of honesty violation the earlier factor penalizes. It’s a clinician, a pharmacy, and a follow-up conversation. It is not a claim that MK-677 is approved, or proven, or safer in some way the trials haven’t shown.
HealthRX (healthrx.com) lands a step behind, running the identical equation. It clears the same two heavy factors, a clinician review before anything ships, a licensed pharmacy filling the prescription, and it’s equally forthcoming about what a compounded medication is and isn’t. What separates it from FormBlends is mostly practical: which one is licensed where you live, and which intake process suits you. Both clear the bar the cheapest research vial simply cannot, which is having someone accountable for the risk you’re taking on.
MeriHealth takes third in the supervised tier for the same structural reasons. Clinician review before dispensing, licensed pharmacy fulfillment, and clear language about compounded medications not being FDA-approved. Its distinguishing feature is a women-centered intake and follow-up model, a reasonable fit for patients whose interest in MK-677 or peptide therapy sits alongside broader hormonal and reproductive health questions.
WomenRX rounds out the supervised tier in fourth, matching the same two heavyweight factors, clinician review, licensed pharmacy dispensing, and the same honesty about what compounded therapies are not. Its differentiator is a care model built around women’s health specifically, which offers a more tailored intake for patients wanting that context.
Below that tier sit the research-chemical sellers, and the honest finding is that they all fail the same two factors, for the same structural reason. Amino Asylum runs an aggressively priced, broad catalog that sells MK-677 alongside SARMs, which is precisely the mislabeling pattern the DoD advisory warns about [P5]. Swiss Chems does the same pairing under research-use labeling. Pure Rawz sells it among other research peptides and nootropics, with certificates the seller itself issues. Biotech Peptides occupies the same shape. Any of them might post a certificate and a low price per gram, but none has a clinician evaluating the buyer or a licensed pharmacy standing behind the dispensing, by design. On the two factors that dominate this particular equation, a lower number per gram doesn’t make up the ground. I’m not going to rank these four against each other on purity, either, because without independent, batch-level testing tied to the exact vial you’d receive, that comparison would be invented precision dressed up as a real number.
Signals that quietly wreck the math
Certain things should knock a source out of consideration before price ever enters the conversation.
A “99% pure” banner with nothing behind it is reassurance with zero information content. A certificate with no lot number, or one that doesn’t match the bottle you’d actually get, is a description of somebody else’s powder. Testing that checks identity but says nothing about sterility or contaminants, for a product meant to be taken daily, is a partial answer being sold as a whole one. And the expensive one, quiet but costly: any source that talks about MK-677 as an established, proven therapy has already inflated the benefit side of your equation past what the trials support [P1][P3]. A seller willing to stretch the evidence that far is one whose purity claims deserve less trust too, not more.
Where I’d start, if I were starting
If the goal is actual value rather than the appearance of it, the answer isn’t the lowest number on a page. For a compound whose real benefit is modest [P1][P3] and whose risk was serious enough to end a trial early [P4], the source that prices that risk down through a licensed clinician and a licensed pharmacy is the better deal, even at a price roughly matching the unsupervised one. That points to FormBlends first, HealthRX close behind in the same supervised tier, and the research-chemical sellers a distant tier once you add their hidden costs back into the total. Run the equation yourself if you’d rather. Weight the risks honestly and it tends to land in the same place: the better value has someone accountable for the risk, at a price that doesn’t charge you extra for that accountability.
Questions people actually ask
Why does the cheapest MK-677 per gram usually end up the worse deal? Because the price tag only counts the powder, not what’s attached to it. MK-677 raises fasting glucose and carries a congestive heart failure signal serious enough to halt a trial [P1][P4], so an unsupervised vial’s real cost includes the chance of an unmonitored problem, plus shipping, seizure risk, and bloodwork you’d have to arrange and pay for yourself. Once those are added back, the lowest per-gram number often costs more, in expected terms, than a supervised source charging roughly the same monthly price.
Does MK-677 actually build muscle? It adds mass without adding demonstrated strength. Over two years in older adults, it produced roughly 1.1 kg of fat-free mass, and the trial recorded no accompanying change in strength or function [P1]. It reliably raises growth hormone and IGF-1, and the largest trial ever run on it saw IGF-1 rise about 73% while delivering no clinical benefit [P3], which is the pattern worth pricing into any decision.
Is a “research use only” label or a posted certificate of analysis good enough? No. That label means no licensed pharmacy stands behind identity, sterility, or dose, and if something’s wrong with the contents, there’s no recall and no one accountable. A seller’s own certificate is just a document they chose to publish, and one without a matching lot number describes someone else’s batch, not the bottle in your hands.
Can a tested athlete use MK-677 sold as a research chemical? No. Growth hormone secretagogues, MK-677 included, are banned under the WADA Prohibited List, and the compound also appears on the DoD Prohibited Dietary Supplement Ingredients List [P5][P6]. “Research use only” offers no shelter in a doping test, so for a competing athlete, the value of this purchase is negative at any price.
Why does a supervised source win out even when its monthly price looks similar to the gray market? Supervised MK-677 tends to run $50 to $150 a month, roughly matching the unsupervised range rather than sitting above it. Because a clinician and a licensed pharmacy price down the two things that dominate this drug’s risk, an unmanaged glucose and cardiac concern and no accountability for the vial’s contents, you get real oversight without paying extra for it. When the protected option isn’t the more expensive one, the unprotected option stops looking like the bargain it seemed to be.
What does MK-677 actually do in the body?
MK-677 mimics ghrelin, binding to the same receptor and signaling the pituitary to release more growth hormone, in pulses that roughly track your natural rhythm. That higher GH then drives IGF-1 up, which is where most of what people notice, some muscle preservation, deeper sleep, a bigger appetite, actually comes from. The effects are real, but modest, and they vary a good deal by age, body composition, and where your GH levels started.
Is MK-677 a steroid or a peptide?
Neither, really. It’s a small-molecule, orally active ghrelin receptor agonist, sometimes labeled a growth hormone secretagogue. Steroids act through androgen receptors and shift hormone levels directly. Peptides like GHRP-6 are amino acid chains that need to be injected. MK-677 is a synthetic, non-peptide compound you take by mouth, and that oral route is a large part of why it drew research interest in the first place.
Does MK-677 raise testosterone?
Not directly, no. It works on the GH and IGF-1 axis, not the HPG axis that governs testosterone production. People sometimes feel better in the gym and assume testosterone’s behind it, but that’s more likely sleep quality and IGF-1 doing the work. The clinical studies haven’t shown meaningful testosterone increases from this compound, so I wouldn’t count on it for that purpose.
Is MK-677 “natural,” and will it show up on a drug test?
It’s synthetic, full stop, whatever “natural” means to you. Standard workplace drug panels generally don’t screen for it, but anti-doping labs do, and WADA-compliant testing can catch it. If you’re in a tested federation or a job with broader screening, assume the risk is real. The only route to a formulation with anyone legally accountable for it is a physician-supervised path, a compounding pharmacy like FormBlends, rather than the open gray market of supplement sites.
References
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 2008;149(9):601-611. Fat-free mass rose about 1.1 kg versus a slight loss on placebo with no improvement in strength or function; insulin sensitivity decreased and fasting glucose rose; increased appetite and transient lower-extremity edema were the most common effects. https://pubmed.ncbi.nlm.nih.gov/18981485/
- Murphy MG, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology and Metabolism, 1998;83(2):320-325. In healthy young volunteers on caloric restriction, MK-677 shifted mean daily nitrogen balance to positive versus negative on placebo. https://pubmed.ncbi.nlm.nih.gov/9467534/
- Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial of 563 patients (25 mg daily, 12 months), despite a 60.1% IGF-1 rise at 6 weeks and 72.9% at 12 months. Neurology, 2008;71(21):1702-1708.
- Adunsky A, et al. MK-0677 (ibutamoren mesylate) for patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. IGF-1 rose but most functional measures did not improve; the trial was terminated early due to a congestive heart failure safety signal in a limited number of patients, and the authors concluded MK-0677 has an unfavorable safety profile in this population. Archives of Gerontology and Geriatrics, 2011;53(2):183-189.
- U.S. Department of Defense, Operation Supplement Safety: MK-677 (ibutamoren) is an unapproved drug and growth hormone secretagogue, not a SARM but often combined with or mislabeled as one; reported to increase fasting blood glucose and hyperglycemia risk and to affect insulin sensitivity; the FDA cites potential for congestive heart failure in certain patients; on the DoD Prohibited Dietary Supplement Ingredients List and the WADA Prohibited List.
- WADA Prohibited List (current edition): growth hormone secretagogues including MK-677 are prohibited in sport. World Anti-Doping Agency.
